Fairfield Financial Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-6,066
Closed -$309K 74
2025
Q4
$309K Sell
6,066
-5,383
-47% -$275K 0.1% 66
2025
Q3
$635K Sell
11,449
-18,909
-62% -$1.11M 0.21% 51
2025
Q2
$2.1M Sell
30,358
-11,469
-27% -$780K 0.73% 32
2025
Q1
$2.9M Sell
41,827
-1,977
-5% -$163K 1.09% 21
2024
Q4
$3.77M Sell
43,804
-8,264
-16% -$894K 1.33% 18
2024
Q3
$6.2M Buy
52,068
+3,605
+7% +$481K 2.11% 14
2024
Q2
$6.92M Buy
+48,463
New +$6.42M 2.04% 14
2023
Q4
$3.9M Buy
37,652
+7,245
+24% +$716K 1.48% 19
2023
Q3
$2.77M Buy
30,407
+7,561
+33% +$666K 1.16% 24
2023
Q2
$1.85M Buy
22,846
+7,380
+48% +$603K 0.74% 29
2023
Q1
$1.22M Buy
15,466
+2,430
+19% +$172K 0.53% 31
2022
Q4
$882K Sell
13,036
-792
-6% -$46.4K 0.4% 33
2022
Q3
$689K Buy
13,828
+1,742
+14% +$93.3K 0.33% 37
2022
Q2
$673K Buy
12,086
+5,080
+73% +$282K 0.31% 38
2022
Q1
$389K Buy
+7,006
New +$360K 0.14% 55

Other funds holding NVO

Fairfield Financial Advisors's NVO Position: Q1 2026 in Review

Fairfield Financial Advisors sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 6,066 shares — an estimated $309K sold.

Fairfield Financial Advisors first reported a position in NVO in Q1 2022 and held it in 15 quarters. The position peaked at $6.92M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Fairfield Financial Advisors reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Fairfield Financial Advisors sold 6,066 Novo Nordisk shares in Q1 2026, an estimated $309K.
  • Fairfield Financial Advisors first reported a position in Novo Nordisk in Q1 2022 and held it in 15 quarters.
  • Fairfield Financial Advisors's Novo Nordisk position peaked at $6.92M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Fairfield Financial Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.